Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Stock analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research note issued on Thursday, January 23rd. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of ($4.19) for the year, down from their prior forecast of ($3.96). HC Wainwright currently has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2027 earnings at ($3.38) EPS, FY2028 earnings at ($3.40) EPS and FY2029 earnings at ($1.40) EPS.
ARWR has been the topic of a number of other reports. Piper Sandler lowered their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Sanford C. Bernstein cut their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. Chardan Capital reiterated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Finally, Citigroup lowered their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $43.33.
Arrowhead Pharmaceuticals Trading Down 2.5 %
NASDAQ:ARWR opened at $20.25 on Monday. Arrowhead Pharmaceuticals has a 12-month low of $17.05 and a 12-month high of $36.72. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The stock’s 50 day simple moving average is $20.76 and its 200-day simple moving average is $21.92. The firm has a market cap of $2.52 billion, a P/E ratio of -4.03 and a beta of 0.97.
Insider Buying and Selling at Arrowhead Pharmaceuticals
In other news, CEO Christopher Richard Anzalone sold 12,563 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $19.59, for a total transaction of $246,109.17. Following the transaction, the chief executive officer now directly owns 3,775,772 shares in the company, valued at $73,967,373.48. This represents a 0.33 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director William D. Waddill sold 3,748 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the completion of the sale, the director now owns 44,125 shares of the company’s stock, valued at approximately $966,337.50. The trade was a 7.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 147,432 shares of company stock worth $2,957,986. 4.50% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Arrowhead Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp grew its position in Arrowhead Pharmaceuticals by 8.8% in the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock valued at $123,083,000 after acquiring an additional 516,569 shares in the last quarter. Geode Capital Management LLC increased its stake in Arrowhead Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after buying an additional 26,171 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Arrowhead Pharmaceuticals by 1.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock worth $19,504,000 after buying an additional 12,574 shares in the last quarter. Millennium Management LLC boosted its position in Arrowhead Pharmaceuticals by 61.9% in the 2nd quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock valued at $13,755,000 after buying an additional 202,280 shares during the last quarter. Finally, abrdn plc grew its stake in shares of Arrowhead Pharmaceuticals by 12.2% during the fourth quarter. abrdn plc now owns 450,075 shares of the biotechnology company’s stock valued at $8,461,000 after acquiring an additional 48,929 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
See Also
- Five stocks we like better than Arrowhead Pharmaceuticals
- Financial Services Stocks Investing
- Sizing Up a New Opportunity for NVIDIA Investors
- Earnings Per Share Calculator: How to Calculate EPS
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Investing in Construction Stocks
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.